Condition: Primary Immune Thrombocytopenia (ITP) · Primary Evans Syndrome (ES) · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to investigate the tolerability of ianalumab (9 mg/kg) with investigator's choice thrombopoietin receptor agonist (IC TPO-RA) in participants diagnosed with primary immune thrombocytopenia (ITP) who have been treated with at least one but no more than four prior treatments, and with no change in IC TPO-RA dose in at least the last 14 days prior to the start of ianalumab.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| Stamford Hospital | Stamford, Connecticut, United States | Recruiting |
| Baptist MD Anderson Cancer Center | Jacksonville, Florida, United States | Recruiting |
| DH Cancer Research Center LLC | Margate, Florida, United States | Recruiting |
| Hope And Healing Care | Hinsdale, Illinois, United States | Recruiting |
| Summit Medical Group | Summit, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07421167